Because tumor‐derived interleukin (IL)‐6 increases hepatic thrombopoietin synthesis and platelet production, as well as increases thrombotic events in patients with ovarian cancer, it has been suggested that interfering with the IL‐6‐thrombopoietin pathway may reduce VTE events.25 This evidence concerns the gene IL6 and ovarian carcinoma.